Riluzole Zentiva
riluzole
Table of contents
Overview
This is a summary of the European public assessment report (EPAR) for Riluzole Zentiva. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Riluzole Zentiva.
Authorisation details
Product details | |
---|---|
Name |
Riluzole Zentiva
|
Agency product number |
EMEA/H/C/002622
|
Active substance |
Riluzole
|
International non-proprietary name (INN) or common name |
riluzole
|
Therapeutic area (MeSH) |
Amyotrophic Lateral Sclerosis
|
Anatomical therapeutic chemical (ATC) code |
N07XX02
|
Publication details | |
---|---|
Marketing-authorisation holder |
Zentiva k.s.
|
Revision |
13
|
Date of issue of marketing authorisation valid throughout the European Union |
07/05/2012
|
Contact address |
U kabelovny 130 |
Product information
15/11/2022 Riluzole Zentiva - EMEA/H/C/002622 - PSUSA/00002645/202112
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Other nervous system drugs
Therapeutic indication
Riluzole Zentiva is indicated to extend life or the time to mechanical ventilation for patients with amyotrophic lateral sclerosis (ALS).
Clinical trials have demonstrated that Riluzole Zentiva extends survival for patients with ALS. Survival was defined as patients who were alive, not intubated for mechanical ventilation and tracheotomy-free.
There is no evidence that Riluzole Zentiva exerts a therapeutic effect on motor function, lung function, fasciculations, muscle strength and motor symptoms. Riluzole Zentiva has not been shown to be effective in the late stages of ALS.
Safety and efficacy of Riluzole Zentiva has only been studied in ALS. Therefore, Riluzole Zentiva should not be used in patients with any other form of motor-neurone disease.